Senior Executive Service Performance Review Board, 53473-53474 [2022-18784]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 168 / Wednesday, August 31, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
the notice indicates that EPA
anticipated allowing registrants to sell
and distribute existing stocks of
chlorpyrifos for one year after the
publication of the cancellation order
and to allow others to sell, distribute,
and use existing stocks until exhausted.
Earthjustice asserts that EPA cannot
allow for existing stocks of chlorpyrifos
to be sold, distributed, or used in this
way as a result of the revocation of all
chlorpyrifos tolerances. See the August
30, 2021 (86 FR 48315) (FRL–5993–04–
OCSPP) publication in the Federal
Register.
The applicability of the existing
stocks language in the April 2022 notice
of receipt to chlorpyrifos products was
an oversight and is being corrected in
this cancellation order. The existing
stocks section of the April 2022 notice
of receipt contained specific language
pertaining to one specific product (not
the chlorpyrifos products) and other
language ‘‘for all other voluntary
cancellations listed in the notice.’’ 87
FR 25259. That language provided broad
existing stocks provisions due to the
Agency’s conclusion that there were ‘‘no
significant potential risk concerns
associated with those pesticide
products.’’ Id. In using somewhat
standard language for a voluntary
cancellation notice, EPA failed to
specify a different existing stocks
provision for the chlorpyrifos products
in the notice, for which tolerances were
revoked due to EPA’s conclusion that
chlorpyrifos tolerances were not safe.
See 87 FR 11222. FIFRA section 6(a)(1)
gives EPA the discretion to permit the
continued sale and use of existing
stocks, where doing so is determined to
be consistent with the purposes of
FIFRA. 7 U.S.C. 136d(a)(1). In the case
of the chlorpyrifos registrations subject
to this order, without tolerances in place
to cover residues from use of these
products, these products may not be
used on food, nor may they be sold or
distributed. Allowing for continued use
or sale would not be consistent with
FIFRA; therefore, EPA is not allowing
for continued sale, distribution, or use
of chlorpyrifos products listed above.
III. The Cancellation Order
Pursuant to FIFRA section 6(f) (7
U.S.C. 136d(f)(1)), EPA hereby approves
the requested cancellations of the
registrations identified in Table 1 of
Unit I. Accordingly, the Agency hereby
orders that the product registrations
identified in Table 1 of Unit I. are
cancelled.
The cancellations and amendments
addressed in this Order are effective
August 31, 2022. Any distribution, sale,
or use of existing stocks of the products
VerDate Sep<11>2014
16:59 Aug 30, 2022
Jkt 256001
identified in Table 1 of Unit I. in a
manner inconsistent with any of the
provisions for disposition of existing
stocks set forth in Unit VI. will be a
violation of FIFRA.
IV. Provisions for Disposition of
Existing Stocks
Existing stocks are those stocks of
registered pesticide products that are
currently in the United States and that
were packaged, labeled, and released for
shipment prior to the effective date of
the cancellation action. The language
regarding the intended disposition of
existing stocks that published in the
Federal Register on April 28, 2022 (87
FR 25256) (FRL–9723–01–OCSPP) on
page 25259 is not appropriate for
application to the pesticide products
subject to this Order.
None of the registrants listed in this
order have requested any continued sale
or distribution of existing stocks of the
registrations subject to this cancellation
order nor have they requested special
provisions to relabel the products listed
in this order. Because of that and
because chlorpyrifos tolerances have
been revoked and use of chlorpyrifos
renders food adulterated, all sale,
distribution, and use of the chlorpyrifos
products identified in Table 1 of Unit I.
is prohibited, except for export
consistent with FIFRA section 17, 7
U.S.C. 136o or for proper disposal.
Dated: August 26, 2022.
Mary Elissa Reaves,
Director, Pesticide Re-Evaluation Division,
Office of Pesticide Programs.
[FR Doc. 2022–18838 Filed 8–30–22; 8:45 am]
BILLING CODE 6560–50–P
53473
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than September 30, 2022.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. Sword Financial Corporation,
Horicon, Wisconsin; to acquire
Community Bancshares Wisconsin and
thereby indirectly acquire Cornerstone
Community Bank, both of Grafton,
Wisconsin.
B. Federal Reserve Bank of Kansas
City (Jeffrey Imgarten, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. First National Buffalo Bankshares,
Inc., Buffalo, Wyoming; to acquire First
State Bank of Newcastle, Newcastle,
Wyoming.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2022–18808 Filed 8–30–22; 8:45 am]
BILLING CODE P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
FEDERAL RETIREMENT THRIFT
INVESTMENT BOARD
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
Senior Executive Service Performance
Review Board
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Federal Retirement Thrift
Investment Board.
ACTION: Notice.
AGENCY:
This notice announces the
appointment of the members of the
Senior Executive Service Performance
Review Board for the Federal
Retirement Thrift Investment Board.
The purpose of the Performance Review
Board is to make written
recommendations on each executive’s
annual summary ratings, performancebased pay adjustment, and performance
awards to the appointing authority.
DATES: This notice is applicable on
August 31, 2022.
SUMMARY:
E:\FR\FM\31AUN1.SGM
31AUN1
53474
Federal Register / Vol. 87, No. 168 / Wednesday, August 31, 2022 / Notices
FOR FURTHER INFORMATION CONTACT:
Kelly Powell, HR Specialist, at 202–
942–1681.
SUPPLEMENTARY INFORMATION: Title 5,
U.S. Code, 4314(c)(4), requires that the
appointment of Performance Review
Board members be published in the
Federal Register before Board service
commences. The following persons will
serve on the Federal Retirement Thrift
Investment Board’s Performance Review
Board which will review initial
summary ratings to ensure the ratings
are consistent with established
performance requirements, reflect
meaningful distinctions among senior
executives based on their relative
performance and organizational results
and provide recommendations for
ratings, awards, and pay adjustments in
a fair and equitable manner: Thomas
Brandt, Jim Courtney, Sean McCaffrey,
and Kim Weaver.
Dharmesh Vashee,
General Counsel, Federal Retirement Thrift
Investment Board.
[FR Doc. 2022–18784 Filed 8–30–22; 8:45 am]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2020–E–2259; FDA–
2020–E–2260; and FDA–2020–E–2261]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; THEROX DOWNSTREAM
SYSTEM
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for THEROX DOWNSTREAM SYSTEM
and is publishing this notice of that
determination as required by law. FDA
has made the determination because of
the submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that medical
device.
DATES: Anyone with knowledge that any
of the dates as published (see
SUPPLEMENTARY INFORMATION) are
incorrect must submit either electronic
or written comments and ask for a
redetermination by October 31, 2022.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:59 Aug 30, 2022
Jkt 256001
extension acted with due diligence
during the regulatory review period by
February 27, 2023. See ‘‘Petitions’’ in
the SUPPLEMENTARY INFORMATION section
for more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
October 31, 2022. Comments received
by mail/hand delivery/courier (for
written/paper submissions) will be
considered timely if they are received
on or before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket Nos. FDA–
2020–E–2259; FDA–2020–E–2260; and
FDA–2020–E–2261 for ‘‘Determination
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
of Regulatory Review Period for
Purposes of Patent Extension; THEROX
DOWNSTREAM SYSTEM.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA’s posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket numbers, found in brackets in
the heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
Rm. 6250, Silver Spring, MD 20993,
301–796–3600.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\31AUN1.SGM
31AUN1
]]>Agencies
[Federal Register Volume 87, Number 168 (Wednesday, August 31, 2022)]
[Notices]
[Pages 53473-53474]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18784]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RETIREMENT THRIFT INVESTMENT BOARD
Senior Executive Service Performance Review Board
AGENCY: Federal Retirement Thrift Investment Board.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the appointment of the members of the
Senior Executive Service Performance Review Board for the Federal
Retirement Thrift Investment Board. The purpose of the Performance
Review Board is to make written recommendations on each executive's
annual summary ratings, performance-based pay adjustment, and
performance awards to the appointing authority.
DATES: This notice is applicable on August 31, 2022.
[[Page 53474]]
FOR FURTHER INFORMATION CONTACT: Kelly Powell, HR Specialist, at 202-
942-1681.
SUPPLEMENTARY INFORMATION: Title 5, U.S. Code, 4314(c)(4), requires
that the appointment of Performance Review Board members be published
in the Federal Register before Board service commences. The following
persons will serve on the Federal Retirement Thrift Investment Board's
Performance Review Board which will review initial summary ratings to
ensure the ratings are consistent with established performance
requirements, reflect meaningful distinctions among senior executives
based on their relative performance and organizational results and
provide recommendations for ratings, awards, and pay adjustments in a
fair and equitable manner: Thomas Brandt, Jim Courtney, Sean McCaffrey,
and Kim Weaver.
Dharmesh Vashee,
General Counsel, Federal Retirement Thrift Investment Board.
[FR Doc. 2022-18784 Filed 8-30-22; 8:45 am]
BILLING CODE 6760-01-P
